Multidisciplinary management of resectable adenocarcinoma of the pancreatic head

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg.223(3), 273–279 (1996).
   PubMedGoogle Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg.120(8), 899–903 (1985).
   PubMed Web of Science ®Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg.230(6), 776–782 (1999); discussion 782–784.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA297(3), 267–277 (2007).
   PubMed Web of Science ®Google Scholar
• Smeenk HG, van Eijck CH, Hop WC et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann. Surg.246(5), 734–740 (2007).
   PubMed Web of Science ®Google Scholar
• Winter JM, Cameron JL, Campbell KA et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J. Gastrointest. Surg.10(9), 1199–1210; discussion 1210–1211 (2006).
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Ko CY et al. National failure to operate on early stage pancreatic cancer. Ann. Surg.246(2), 173–180 (2007).
   PubMed Web of Science ®Google Scholar
• Hwang RF, Wang H, Lara A et al. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann. Surg. Oncol.15(5), 1356–1366 (2008).
   PubMedGoogle Scholar
• Pawlik TM, Laheru D, Hruban RH et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann. Surg. Oncol.15, 2081–2088 (2008).
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID et al. Exocrine pancreas. In: AJCC Cancer Staging Manual (6th Edition). Fritz A (Ed.). Springer-Verlag, NY, USA 157–164 (2002).
   Google Scholar
• Katz MH, Hwang R, Fleming JB, Evans DB. Tumor–node–metastasis staging of pancreatic adenocarcinoma. CA Cancer J. Clin.58(2), 111–125 (2008).
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Ko CY et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer110(4), 738–744 (2007).
   PubMed Web of Science ®Google Scholar
• Katz MH, Moossa AR, Bouvet M. Laparoscopic staging of pancreatic cancer. In: MD Anderson Solid Tumor Oncology Series: Pancreatic Cancer. Lowy AM, Leach S, Philip P (Eds). Springer, NY, USA 285–312 (2008).
   Google Scholar
• Evans DB, Crane CH, Charnsangavej C, Wolff RA. The added value of multidisciplinary care for patients with pancreatic cancer. Ann. Surg. Oncol.15(8), 2078–2080 (2008).
   PubMedGoogle Scholar
• Kuhlmann KF, de Castro SM, Wesseling JG et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur. J. Cancer40(4), 549–558 (2004).
   PubMed Web of Science ®Google Scholar
• Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann. Surg.221(1), 59–66 (1995).
   PubMed Web of Science ®Google Scholar
• Wenger FA, Peter F, Zieren J et al. Prognosis factors in carcinoma of the head of the pancreas. Dig. Surg.17(1), 29–35 (2000).
   PubMedGoogle Scholar
• Willett CG, Lewandrowski K, Warshaw AL et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann. Surg.217(2), 144–148 (1993).
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Tamm EP, Abbruzzese JL et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann. Surg. Oncol.13(8), 1035–1046 (2006).
   PubMed Web of Science ®Google Scholar
• Tseng JF, Raut CP, Lee JE et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J. Gastrointest. Surg.8(8), 935–949; discussion 949–950 (2004).
   PubMed Web of Science ®Google Scholar
• Howard TJ, Villanustre N, Moore SA et al. Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head. J. Gastrointest. Surg.7(8), 1089–1095 (2003).
   PubMedGoogle Scholar
• Jaeck D, Bachellier P, Oussoultzoglou E et al. [Analysis of a series of 100 mesenterico-portal vein resections during pancreatic resection]. Bull. Acad. Natl Med.190(7), 1495–1506; discussion 1506–1509 (2006).
   PubMedGoogle Scholar
• Loyer EM, David CL, Dubrow RA et al. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom. Imaging21(3), 202–206 (1996).
   PubMedGoogle Scholar
• Lightner AM, Glasgow RE, Jordan TH et al. Pancreatic resection in the elderly. J. Am. Coll. Surg.198(5), 697–706 (2004).
   PubMedGoogle Scholar
• Bachmann J, Heiligensetzer M, Krakowski Roosen H et al. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J. Gastrointest. Surg.12(7), 1193–201 (2008).
   PubMed Web of Science ®Google Scholar
• Ishii H, Okada S, Nose H et al. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas12(3), 267–271 (1996).
   PubMedGoogle Scholar
• Klaassen DJ, MacIntyre JM, Catton GE et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil – an Eastern Cooperative Oncology Group study. J. Clin. Oncol.3(3), 373–378 (1985).
   PubMed Web of Science ®Google Scholar
• Krishnan S, Rana V, Janjan NA et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer107(11), 2589–2596 (2006).
   PubMed Web of Science ®Google Scholar
• Sezgin C, Karabulut B, Uslu R et al. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scand. J. Gastroenterol.40(12), 1486–1492 (2005).
   PubMed Web of Science ®Google Scholar
• Brown KM, Siripurapu V, Davidson M et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am. J. Surg.195(3), 318–321 (2008).
   PubMed Web of Science ®Google Scholar
• Katz MH, Pisters PW, Evans DB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J. Am. Coll. Surg.206(5), 833–846; discussion 846–848 (2008).
   PubMed Web of Science ®Google Scholar
• Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann. Surg.237(1), 74–85 (2003).
   PubMed Web of Science ®Google Scholar
• Howard TJ, Krug JE, Yu J et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer. J. Gastrointest. Surg.10(10), 1338–1345; discussion 1345–1346 (2006).
   PubMed Web of Science ®Google Scholar
• Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann. Surg.211(4), 447–458 (1990).
   PubMed Web of Science ®Google Scholar
• Birkmeyer JD, Finlayson SR, Tosteson AN et al. Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery125(3), 250–256 (1999).
   PubMed Web of Science ®Google Scholar
• Birkmeyer JD, Warshaw AL, Finlayson SR et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery126(2), 178–183 (1999).
   PubMed Web of Science ®Google Scholar
• Meguid RA, Ahuja N, Chang DC. What constitutes a “high-volume” hospital for pancreatic resection? J. Am. Coll. Surg.206(4), 622 E1–E9 (2008).
   PubMedGoogle Scholar
• Milstein A, Galvin RS, Delbanco SF et al. Improving the safety of health care: the leapfrog initiative. Eff. Clin. Pract.3(6), 313–316 (2000).
   PubMedGoogle Scholar
• Bilimoria KY, Bentrem DJ, Ko CY et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer110(6), 1227–1234 (2007).
   PubMed Web of Science ®Google Scholar
• Birkmeyer JD, Dimick JB. Potential benefits of the new Leapfrog standards: effect of process and outcomes measures. Surgery135(6), 569–575 (2004).
   PubMedGoogle Scholar
• Katz MH, Wang H, Fleming JB et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann. Surg. Oncol. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Neoptolemos JP, Dunn JA, Stocken DD et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet358(9293), 1576–1585 (2001).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med.350(12), 1200–1210 (2004).
   PubMed Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6), 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Neuhaus P, Riess H, Post S et al. CONKO 001: final results of the randomized, prospective, multicenter Phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J. Clin. Oncol.26(20 Suppl.), (2008) (Abstract LBA4504).
   Google Scholar
• Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA299(9), 1019–1026 (2008).
   PubMed Web of Science ®Google Scholar
• Butturini G, Stocken DD, Wente MN et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch. Surg.143(1), 75–83; discussion 83 (2008).
   PubMedGoogle Scholar
• Stocken DD, Buchler MW, Dervenis C et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br. J. Cancer92(8), 1372–1381 (2005).
   PubMed Web of Science ®Google Scholar
• Abrams RA, Lillemoe KD, Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet258(9293), 1565–1566 (2001).
   Google Scholar
• Herman JM, Swartz MJ, Hsu CC et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J. Clin. Oncol.26(21), 3503–3510 (2008).
   PubMed Web of Science ®Google Scholar
• Wolff RA, Varadhachary GR, Evans DB. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann. Surg. Oncol.15(10), 2773–2786 (2008) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP. Clinical evidence does not support the use of adjuvant radiotherapy in pancreatic cancer. Nat. Clin. Pract. Oncol.5(8), 431 (2008).
   PubMedGoogle Scholar
• Aloia TA, Lee JE, Vauthey JN et al. Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? J. Am. Coll. Surg.204(3), 347–355 (2007).
   PubMed Web of Science ®Google Scholar
• Wayne JD, Abdalla EK, Wolff RA et al. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist7(1), 34–45 (2002).
   PubMed Web of Science ®Google Scholar
• Breslin TM, Hess KR, Harbison DB et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann. Surg. Oncol.8(2), 123–132 (2001).
   PubMed Web of Science ®Google Scholar
• Sasson AR, Wetherington RW, Hoffman JP et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int. J. Gastrointest. Cancer34(2–3), 121–128 (2003).
   PubMedGoogle Scholar
• White RR, Xie HB, Gottfried MR et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann. Surg. Oncol.12(3), 214–221 (2005).
   PubMedGoogle Scholar
• Pingpank JF, Hoffman JP, Ross EA et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J. Gastrointest. Surg.5(2), 121–130 (2001).
   PubMed Web of Science ®Google Scholar
• Greer SE, Pipas JM, Sutton JE et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J. Am. Coll. Surg.206(3), 451–457 (2008).
   PubMedGoogle Scholar
• Kim HJ, Czischke K, Brennan MF, Conlon KC. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J. Gastrointest. Surg.6(5), 763–769 (2002).
   PubMed Web of Science ®Google Scholar
• White R, Lee C, Anscher M et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann. Surg. Oncol.6(1), 38–45 (1999).
   PubMedGoogle Scholar
• White RR, Hurwitz HI, Morse MA et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann. Surg. Oncol.8(10), 758–765 (2001).
   PubMed Web of Science ®Google Scholar
• Talamonti MS, Small W Jr, Mulcahy MF et al. A multi-institutional Phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann. Surg. Oncol.13(2), 150–158 (2006).
   PubMed Web of Science ®Google Scholar
• Mornex F, Girard N, Scoazec JY et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97–04 Phase II trial. Int. J. Radiat. Oncol. Biol. Phys.65(5), 1471–1478 (2006).
   PubMed Web of Science ®Google Scholar
• Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the Surveillance, Epidemiology, And End Results (SEER) Registry. Int. J. Radiat. Oncol. Biol. Phys. (2008).
   PubMedGoogle Scholar
• Vulfovich M, Rocha-Lima C. Novel advances in pancreatic cancer treatment. Exp. Rev. Anticancer Ther.8(6), 993–1002 (2008).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(15), 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar